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Abstract
Objectives: In advanced stages, hepatocellular carcinoma (HCC) is often associated with major vas-
cular involvement (cava, portal vein). The aim of the present study was to analyse the role of surgical
resection (SR) and loco-regional therapy (LRT) in these advanced stage patients to determine if there
was a survival benefit.
Methods: The study is a retrospective analysis from the Commission on Cancer’s National Cancer
Data Base (NCDB) from 1998 to 2011. In total, 148 882 patients with liver cancer were identified, of
which 126 984 had HCC. Of these, 64 264 patients (1998–2006) had 5-year survival data available and
8825 patients had Stage 3A disease based on AJCC classification. Of these patients, 884 had SR, 771
had LRT and 7170 patients had neither intervention. Kaplan–Meier curves and log-rank tests were
used for statistical analysis.
Results: Eight thousand eight hundred and twenty-five patients met analysis criteria. The mean age
(years) in the SR, LRT and no intervention group were 62.5, 64.3 and 64.2, respectively. Most patients
were males in all three groups (77.5%, 74.5% and 68.1%). The mean tumour size (cm) in the three
groups was 9.8, 6.4 and 8.4, respectively. SR and LRT were primarily performed in major academic
and comprehensive cancer programmes compared with community cancer programmes and other
centres (SR: 93% versus 7%; LRT: 94.6% versus 5.4%). The median 5-year survival (months) was
26.6 in SR, 16.5 in LRT and 4.8 in the no intervention group (P < 0.0001).
Conclusion: A SR and LRT offer a survival benefit in select patients diagnosed with Stage 3A HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the most common primary
malignant tumour in the adult liver. 30 640 new cases and
21 670 deaths were recorded in 2014 by the National Cancer
Institute in the US. It is the 5th most frequently diagnosed
cancer in men and the 2nd leading cause of cancer-related
death in the world.1
The primary modality of treatment for HCC has been a sur-
gical resection (SR) or transplantation when feasible.2 Unfortu-
nately, most patients at the time of initial presentation and
evaluation have advanced disease, which is not amenable to a
SR. Over the past decade, this ideology has been challenged by
many surgeons across the world and there has been an
increased propensity towards a more aggressive surgical
approach in patients with locally advanced disease with vascu-
lar involvement.3–5
The oncological principles towards cancer surgery still apply
to this group of patients. The tumour has to be resected with
negative margins to achieve the best outcomes. In the
This study was presented at the Annual Meeting of the AHPBA, 19-23
February 2014, Miami, Florida.
HPB 2015, 17, 964–968 ª 2015 International Hepato-Pancreato-Biliary Association
DOI:10.1111/hpb.12466 HPB
advanced stages of HCC, this would include resection of the
major vascular structures with complex reconstruction also to
the primary tumour resection. These procedures require the
highest degree of expertise in hepatobiliary and transplant sur-
gery; therefore, the access to healthcare offering high-quality
expertise to all is very important to consider when discussing
the outcomes. Not every patient diagnosed with tumours in
these advanced stages has access to centres of excellence
performing these procedures.
Hence, it was chosen to perform a retrospective analysis of
patients with Stage 3A HCC (AJCC Staging 5th and 6th edn)
from the National Cancer Database. The primary endpoint was
to determine if a SR had an overall survival benefit compared
with no treatment in advanced stage HCC patients. Our sec-
ondary endpoint was to define the socioeconomic factors that
could potentially play a significant role with respect to the
modality of treatment one would receive and their overall
survival.
Patients and methods
Data acquisition and patient selection
Instituted in 1989, The National Cancer Data Base (NCDB)
is a nationwide oncology outcomes database from more than
1500 commission-accredited cancer programmes in the Uni-
ted States and Puerto Rico. It is a joint programme of the
Commission on Cancer (CoC) of the American College of
Surgeons and the American Cancer Society. Approximately
70% of all newly diagnosed cases are captured at the centre
and submitted to the NCDB. The database has approxi-
mately 29 million records from hospital cancer registries
across the United States. The key components of the data-
base include patient demographics, cancer diagnostics, clini-
cal and pathological staging, treatment details (surgery,
radiation, chemotherapy and palliative) and survival. Also,
socioeconomic information and insurance information are
also captured.
Using the NCDB, patients with HPC were identified accord-
ing to the International Classification of Diseases for Oncology
(3rd edn). There were 126 984 patients diagnosed with HCC
between the years 1998 and 2011. For the purpose of the study,
the cohort was restricted to the years 1998–2006 (64 264) to
obtain 5-year survival data. Eight thousand eight hundred
twenty-five patients had stage 3A disease at the time of diagno-
sis (Fig. 1). Subgroup analyses were also performed with the
following variables: tumour size, race, facility type, median
income by zipcode and insurance status at the time of evalua-
tion.
Statistical analysis
Descriptive statistics, including counts, percentages, means and
standard deviations, were calculated for patient specific demo-
graphics. Survival was calculated in months from the date of
diagnosis to the date of death or last contact. The overall sur-
vival was estimated using Kaplan–Meier estimates. The log-
rank test was used to analyse the statistical significance of the
Kaplan–Meier estimates. Cox’s proportional hazard models
were used for univariate and multivariate analyses of the time-
to-event data. Multivariate Cox’s proportional hazard models
adjusted for the procedure, tumour size, race, age, gender,
insurance status, facility type and the median household
income. SAS Enterprise Guide, version 5.1, was used for all
analyses. A two-tailed P-value of less than 0.05 was considered
statistically significant.
Results
Patient demographics
Seventy-seven thousand four hundred and sixty patients diag-
nosed with liver cancer from 1998 to 2006 were included in
the NCDB of which 64 264 (83%) had HCC as the primary
diagnosis. The group of interest was the patients with Stage 3A
HCC (8825). Eight hundred and eighty-four (10.0%) patients
underwent a SR, 771 (8.7%) had loco-regional therapy (LRT)
in the form of radio-frequency ablation, cryosurgery and alco-
hol injection. Seven thousand one hundred seventy (81.3%)
patients had no intervention (Fig. 1). The mean age (years) in
the SR, LRT and no intervention groups were 62.5, 64.3 and
64.2, respectively. Most patients were males in all three groups
(67.4%, 73.4% and 76.3%).
Survival data
Patients with Stage 3A HCC undergoing a SR had the best
overall median survival (26.6 months) followed by those who
underwent LRT (16.4 months) The patients who had no treat-
ment had the worst prognosis (4.8 months). Females had a
better overall survival across all three groups compared with
males (Fig. 2).
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884
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Figure 1 Patient selection flowchart. HCC, hepatocellular
carcinoma
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Subgroup analysis
Race
Caucasians (n = 1291) had the best median survival for both
the SR and LRT (27.2 months – SR, 16.3 months. – LRT). In
contrast, African Americans (n = 171) had a lower survival
rate in both groups (21.2 months – SR, 12.8 months – LRT).
Tumour size
Tumour size was divided into two categories [<5 cm
(n = 1727) and >5 cm (n = 5541)]. Patients with smaller
tumours (<5 cm) had a better overall survival (32.4 months
versus 24.7 months – SR, 19.7 months versus 15.3 months –
LRT). Patients who underwent SR in the <5 cm group did do
better than those who received LRT (32.4 months versus
19.7 months P < 0.0001).
Facility type
There was a total of four groups: Academic/Research NCI-des-
ignated centres (n = 1093), Comprehensive Community
Cancer Program (n = 497), Community Cancer Programme
(n = 87) and Other Centres. The best outcomes were achieved
at the academic/research NCI-designated centres followed by
the comprehensive community cancer programmes (Table 1).
Median income by zipcode
The data were computed based on the zip-code location. The
patients were divided into four groups as detailed in Table 1.
The outcomes based on resection and locoregional therapy
remained unaffected amongst the various groups.
Insurance type
Patients were grouped based on the type of insurance they pre-
sented with to the hospital for diagnosis and treatment. The
types of insurance included private, Medicare, Medicaid and
uninsured. Patients with private insurance had the best
outcomes overall in both the resection and locoregional ther-
apy groups (Table 1).
Discussion
The surgical treatment of advanced stage HCC involving major
vascular structures is tedious and complex. It usually involves
extended resections with major vascular reconstruction. Over
the last decade, there has been convincing evidence in the pub-
lished literature that the overall survival after SR in advanced
stage HCC is better than LRT.3–8 Liu et al. recently published
on the outcomes of surgical resection for BCLC Stage C HCC
(BCLC – Barcelona Clinic Liver Cancer). They were able to
show that a resection provided significantly better long-term
survival than transarterial chemoembolization (TACE) in
patients with BCLC stage C HCC.7 Peng et al., in their case
review comparing a hepatic resection to TACE for the treat-
ment of HCC with portal vein tumour thrombus, were able to
show that a resection provided survival benefits for patients
with HCC and tumour thrombus involving the right or left
portal vein or their segmental branches.9 There are certain fac-
tors that definitely should be taken into consideration when
deciding to operate on these patients to be able to provide the
best possible outcomes. The degree of fibrosis and the presence
or absence of cirrhosis would be of utmost importance. The
synthetic function of the liver in addition to the other comor-
bidities of the patient including performance status will need
to be taken into account.10
Major SR (lobectomy and trisectionectomy) has traditionally
been reserved for patients with preserved liver function and in
non-cirrhotic patients. In order to perform resections involving
vascular reconstruction, one will need to perform a hepatic
venous occlusion (partial or complete) depending on the pri-
mary tumour location and portal vein occlusion when
needed.11 The techniques of ex vivo resection and in situ cold
perfusion have also been described.12–15 Patients with advanced
stage HCC in the setting of a non-cirrhotic liver have the abil-
ity to tolerate these procedures.16 In contrast, patients with
Stage 3A HCC in the setting of background cirrhosis have a
limited synthetic reserve and are not ideal candidates for major
resections.17 These patients either receive LRT in the form of
transarterial chemoembolization or thermal ablation (done
percutaneously or laparoscopically) in the palliative setting.18
Chemotherapy in the form of Sorafenib has also been used in
patients with advanced stage HCC with equivocal results.19,20
Our primary aim was to use the National Cancer Database
and identify the group of patients with stage 3A HCC and
determine if there was a long-term survival benefit in patients
who under SR. We were also interested in determining the fac-
tors that influenced the type of treatment if any that the
patient got when they presented to the hospital. Our results
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Figure 2 Kaplan–Meier curve comparing the survival of patients
with Stage 3A hepatocellular carcinoma (HCC) after a surgical
resection (SR), locoregional therapy (LRT) and no procedure
HPB 2015, 17, 964–968 ª 2015 International Hepato-Pancreato-Biliary Association
966 HPB
indicate that patients who underwent SR had a better overall
survival than the group who had no therapy (26.6 versus
4.8 months). The group that underwent LRT had a median
survival of 16.4 months. Patients with tumours < 5 cm had a
better survival with both forms of treatment (SR and LRT).
Our analysis also revealed that the best outcomes after
surgery were achieved at Academic/Research NCI-designated
centres (27.7 months) followed by Comprehensive Community
Cancer Programmes (26.5 months). We believe this to be con-
sistent with the fact that most of the resections were performed
at these centres (Table 1) and hence the better survival owing
to the level of expert care available. From a socioeconomic
standpoint, patients with private insurance had the best
survival but surprisingly a median income did not affect
median survival. We believe the reason for this observation is
as a result of the fact the US healthcare system makes it
mandatory to provide the best care available to a patient when
they present to a facility irrespective of their income status.
The primary limitations of our study are to do with the
staging system used to identify the patients in the database and
inherent deficiencies that accompany a retrospective study. The
AJCC staging system is a very comprehensive and detail-ori-
ented system used widely in cancer staging; yet it does not
include enough information to compute the model of end-
stage liver disease scores for the group of patients included in
the study and there is limited information on liver function.
The database does not include information on disease
recurrence. Most of the therapy for HCC these days are
multi-modality based but this information is also lacking in
the database. Last, but not the least, is the details on patient
comorbidities and lack of data on timing of locoregional
chemotherapy. Radioembolization using Yttrium-90 is a
modality used these days in patients with advanced stage HCC.
Unfortunately, there is no data captured for this form of LRT.
We also believe there is a certain degree of selection bias intro-
duced with the mode of therapy offered to patients based on
their disease burden and overall functional status.
As the database has information on patients until 2011 but
has clear instructions not to use data for survival analysis
unless the patients have been followed up for 5 years, we
restricted our patient cohort accordingly for the purpose of the
study. Nonetheless, the information on the presence or absence
of cirrhosis and its relationship with surgical intervention and
LRT for advanced stage HCC was recorded in more detail in
subsequent years and we did a basic analysis to look at the
effects of cirrhosis on survival in patients who were treated
surgically. One hundred and eighty-nine patients with stage 3A
HCC were identified with data on the degree of fibrosis and
cirrhosis. The median survival for Stage 3A HCC patients with
a none-to-moderate degree of fibrosis (n = 123) was 35.8
Table 1 Subgroup analyses
Subgroups N Hazard Ratio 95%
confidence
Intervals
SR (months.) LRT (months.) P-value
Race
Caucasians (ref) 1291 27.2 16.33 <0.0001
African American 171 1.371 1.143 1.644 21.16 12.81 0.048
Other 255 0.918 0.785 1.072 24.25 22.54 0.051
Facility type
Academic/Research NCI designated (ref) 1093 27.73 17.48 <0.0001
Comprehensive Cancer Programmes 497 1.133 1.006 1.276 26.48 14.23 <0.0001
Community Cancer Programmes 87 1.585 1.242 2.021 17.74 12.71 0.079
Other 40 1.581 1.038 2.408 15.7 15.28 0.9234
Median income
>$46 000 (ref) 619 29.14 19.38 0.0002
$35 000–$45 999 450 1.143 0.996 1.311 24.74 15.28 <0.0001
$30 000–$34 999 297 1.131 0.964 1.326 31.05 13.84 <0.0001
<$30 000 257 1.170 0.985 1.389 21.19 16.82 0.024
Insurance type
Private (ref) 645 28.52 15.84 <0.0001
Medicaid 139 1.083 0.879 1.334 22.93 21.62 0.102
Medicare 788 1.214 1.073 1.375 25.79 16.16 <0.0001
Not insured 45 0.965 0.682 1.366 23.06 16.79 0.376
Other Government 15 1.330 0.725 2.440 13.79 16.84 0.960
SR, surgical resection; LRT, locoregional therapy.
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compared with 15.7 months in the severe fibrosis-to-cirrhosis
group (n = 66; P = 0.09). When compared with LRT, the
group with severe fibrosis or cirrhosis who underwent a SR
had a similar median survival (15.3 for LRT versus 15.7 for
SR). In the none-to-moderate fibrosis group, the median sur-
vival for the LRT group (n = 22) was 13.4 months compared
with 35.8 months in the resection group (n = 123, P = 0.09).
These data are purely for reference purpose and not to be
taken as part of our results but it does show that the survival
of patients with cirrhosis after a resection is not different from
LRT and, hence, can be offered as a treatment option when
indicated.
The National Cancer Database provides a wealth of informa-
tion with regards to patients with liver-associated malignancies.
The detail of information could be significantly improved by
including vital information including the synthetic function of
the liver, MELD score, the inclusion of TACE as part of the
LRT and patient comorbidities. Some of this information is
available in the more recent data as mentioned above and in
time; most of the limitations in this study could be addressed
suitably.
To our knowledge, this is the largest retrospective analysis to
determine the survival benefit of a resection in patients with
advanced HCC in the United States. Patients with advanced
stage HCC involving the major vasculature do have a survival
benefit with SR when performed in the right setting. Our
analyses revealed that SR and LRT were primarily performed
in major academic and comprehensive cancer programmes
compared with community programmes and other centres.
Socioeconomic factors had a significant impact on survival
most probably owing to accessibility to healthcare, the effect of
the timely intervention and the extent of adequate post-opera-
tive care and follow-up.
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